Research Article
Characterizing the Assessment and Management of Vitamin D Levels in Patients with Osteoporosis in Clinical Practice: A Chart Review Initiative
Table 1
Patient characteristics.
| Characteristic | Percentag | Sample size |
| Gender (female) | 87.8% | 983 | Age | | 983 | <50 years | 2.0% | | 50–59 years | 14.5% | | 60–69 years | 30.0% | | 70–79 years | 33.7% | | ≥80 years | 19.7% | | BMD based on most recent lowest -score, mean (SD) | −2.16 (1.55) | 946 | Additional fracture risk factors | | 977 | Previous fragility fracture | 27.8% | | Systemic glucocorticoids for >3 months | 8.5% | | Previous fragility fracture and systemic glucocorticoids for >3 months | 3.3% | | Length of treatment for osteoporosis | | 980 | <1 year | 11.3% | | 1–5 years | 43.8% | | >5 years | 44.9% | | Osteoporosis therapy | | 983 | Bisphosphonate | 79.0% | | Selective estrogen-receptor modulator | 3.0% | | Hormone therapy | 2.3% | | Parathyroid hormone | 2.2% | | Calcitonin | 1.3% | | Prescribed supplementation | | 983 | Calcium | 84.8% | | Vitamin D | 84.8% | |
|
|
Except for BMD, for which the mean (SD) is presented. BMD = bone mineral density; SD = standard deviation.
|